C
Chris Brawley
Publications - 8
Citations - 1286
Chris Brawley is an academic researcher. The author has contributed to research in topics: Prostate cancer & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 922 citations.
Papers
More filters
Journal ArticleDOI
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Journal ArticleDOI
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
Nicholas D. James,Noel W. Clarke,Adrian Cook,Adnan Ali,Alex Hoyle,Gerhardt Attard,Chris Brawley,Simon Chowdhury,William Cross,David P. Dearnaley,Johann S. de Bono,Carlos Diaz Montana,Duncan C. Gilbert,Silke Gillessen,Clare Gilson,Robert Jones,Ruth E Langley,Zafar Malik,David Matheson,Robin Millman,Chris Parker,C. Pugh,H. Rush,J. Martin Russell,D. Berthold,Michelle L Buckner,Malcolm David Mason,Alastair W. S. Ritchie,Alison Birtle,Susannah Brock,Prantik Das,Daniel Ford,Joanna Gale,W. Grant,E. Gray,Peter Hoskin,Mohammad Monis Khan,C. Manetta,Neil McPhail,Joe M. O'Sullivan,Omi Parikh,Carla Perna,Carmel Pezaro,Andrew Protheroe,Angus Robinson,Sarah Rudman,D. Sheehan,Narayanan Srihari,Isabel Syndikus,Jacob Tanguay,Carys Thomas,Salil Vengalil,John Wagstaff,James D. Wylie,Mahesh K. B. Parmar,Matthew R. Sydes +55 more
TL;DR: A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group.
Journal ArticleDOI
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
Chris Parker,Nicholas D. James,Chris Brawley,Noel W. Clarke,Adnan Ali,Claire Amos,Gerhardt Attard,Simon Chowdhury,Adrian Cook,William Cross,David P. Dearnaley,Hassan Douis,Duncan C. Gilbert,Clare Gilson,Silke Gillessen,Alex Hoyle,Robert H. Jones,Ruth E Langley,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,Mary Rauchenberger,H. Rush,J. Martin Russell,Hannah Sweeney,Amit Bahl,Alison Birtle,L. Capaldi,O.S. Din,Daniel Ford,Joanna Gale,Ann Henry,Peter Hoskin,Mohammed Kagzi,Anna Lydon,Joe M. O'Sullivan,S. Paisey,Omi Parikh,Delia Pudney,Vijay A C Ramani,Peter Robson,Narayanan Srihari,Jacob Tanguay,Mahesh K. B. Parmar,Matthew R. Sydes +45 more
TL;DR: In this paper , the authors report long-term findings on the primary outcome measure of OS and on the secondary outcome measures of symptomatic local events, RT toxicity events, and quality of life (QoL).
Journal ArticleDOI
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
Nicholas D. James,Fiona C. Ingleby,Noel W. Clarke,Claire Amos,Gerhardt Attard,Chris Brawley,Simon Chowdhury,William Cross,David P. Dearnaley,Duncan C. Gilbert,Silke Gillessen,Robert Jones,Ruth E Langley,Archie Macnair,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,Chris Parker,H. Rush,J. Martin Russell,Carly Au,Alastair W. S. Ritchie,Ricardo Pereira Mestre,Imtiaz Ahmed,Alison Birtle,Susannah Brock,Prantik Das,Victoria Ford,E. Gray,Robert Hughes,C. Manetta,Duncan McLaren,A. Nikapota,Joe M. O'Sullivan,Carla Perna,Clive Peedell,Andrew Protheroe,Santhanam Sundar,Jacob Tanguay,Shaun Tolan,John Wagstaff,Jan Wallace,James D. Wylie,Anjali Zarkar,Mahesh K. B. Parmar,Matthew R. Sydes +46 more
TL;DR: There is robust evidence that SOC plus docetaxel improved FFS and PFS (previously shown to increase quality-adjusted life-years), without excess late toxicity, which did not translate into benefit for longer-term outcomes.
Journal ArticleDOI
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
Caroline S. Clarke,Rachael Hunter,Andrea Gabrio,Chris Brawley,Fiona C. Ingleby,David P. Dearnaley,David Matheson,Gerhardt Attard,H. Rush,Robert Jones,William Cross,Chris Parker,J. Martin Russell,Robin Millman,Silke Gillessen,Zafar Malik,Jason F. Lester,James D. Wylie,Noel W. Clarke,Mahesh K. B. Parmar,Matthew R. Sydes,Nicholas D. James +21 more
TL;DR: AAP is effective for non-metastatic and metastatic disease but is not cost-effective when using the BNF price, and Broadening AAP’s indication and having a daily cost below the thresholds described above is recommended, given AAP improves survival in both subgroups and its cost-saving potential in M0 subgroup.